RenovoRx Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
RNXT Nasdaq 8731 https://renovorx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for RenovoRx Inc

We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully - Sep 26th, 2024 11:29 am
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians - Sep 25th, 2024 12:30 pm
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer - Sep 19th, 2024 12:30 pm
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York - Aug 27th, 2024 12:30 pm
RenovoRx continues drug-device combo Phase III trial in pancreatic cancer - Aug 14th, 2024 4:13 pm
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - Aug 14th, 2024 12:30 pm
RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist® - Jul 31st, 2024 12:30 pm
RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist® - Jul 8th, 2024 12:30 pm
University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial - Jun 26th, 2024 12:30 pm
RenovoRx CEO Issues Update Letter to Shareholders - May 30th, 2024 12:30 pm
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery - May 21st, 2024 1:00 pm
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024 - May 14th, 2024 1:00 pm
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024 - May 2nd, 2024 1:00 pm
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement - Apr 18th, 2024 12:30 pm
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting - Apr 16th, 2024 12:30 pm
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026 - Apr 15th, 2024 12:00 pm
RenovoRx Announces $11.1 Million at Market Private Placement - Apr 8th, 2024 12:30 pm
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024 - Apr 5th, 2024 12:30 pm
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024 - Mar 12th, 2024 1:00 pm
RenovoRx Highlights Key Leadership Promotions - Mar 8th, 2024 9:05 pm